PVLA

Palvella Therapeutics, Inc. Common Stock

PVLA

Market cap $653M

Overview Fund Activity

59.04 USD

+2.47

4.37%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

59.04

0.00

0%

1 day

4.37%

5 days

0.48%

1 month

19.15%

3 months

187.86%

6 months

111.92%

Year to date

392%

1 year

265.35%

5 years

-74.98%

10 years

-71.62%

About: Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Employees: 14

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

1,300% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 2

111% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 9

63% more funds holding

Funds holding: 41 [Q1] → 67 (+26) [Q2]

7.79% more ownership

Funds ownership: 45.66% [Q1] → 53.45% (+7.79%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 2 (+0) [Q2]

7% less capital invested

Capital invested by funds: $143M [Q1] → $133M (-$10.2M) [Q2]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$54

9% downside

Avg. target

$69

18% upside

High target

$90

52% upside

7 analyst ratings

7 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Trevor Allred	$85	Outperform Initiated	9 Sep 2025
Canaccord Genuity Whitney Ijem	$66	Buy Maintained	19 Aug 2025
HC Wainwright & Co. Andrew S. Fein	$75	Buy Maintained	15 Aug 2025
Chardan Capital Geulah Livshits	$60	Buy Maintained	15 Aug 2025
Raymond James Ryan Deschner	$54	Outperform Initiated	6 Aug 2025
LifeSci Capital Sam Slutsky	$90	Outperform Initiated	4 Aug 2025
Truist Securities Danielle Brill	$56	Buy Initiated	21 Jul 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about PVLA published over the past 30 days

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Recent advances in understanding venous malformation disease pathogenesis highlight the PI3K/AKT/mTOR pathway as a key driver of disease proliferation, spurring real-world off-label use of systemic rapamycin (sirolimus) Publication includes a systematic review of 26 studies evaluating the use of rapamycin for the treatment of venous malformations Study authors highlight unmet clinical need for venous malformations and lack of FDA-approved pharmacologic options while advocating for an FDA-approved targeted topical formulation of rapamycin for patients with cutaneous venous malformations WAYNE, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced the publication of a manuscript in Lymphatic Research and Biology which summarizes a systematic literature review of rapamycin for the treatment of venous malformations (VMs).

Palvella Therapeutics Announces Scientific Publication in Lymphatic Research and Biology Highlighting Recent Advances in the Pathogenesis of Venous Malformations and the Real-World Use of Rapamycin as an Emerging Targeted Therapy

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Phase 2 TOIVA trial successfully met recruitment target, enrolling 16 subjects at leading vascular anomaly centers; top-line data expected in mid-December 2025

Palvella Therapeutics Completes Enrollment in Phase 2 TOIVA Trial of QTORIN™ Rapamycin for Cutaneous Venous Malformations

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Co-Founder and former Chief Technical Officer of Arcutis Biotherapeutics brings extensive topical product development experience, including track record of translating science into commercially available therapies

Palvella Therapeutics Strengthens Leadership with Appointment of Accomplished Scientist and Biopharmaceutical Executive David W. Osborne, Ph.D.

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will present at two upcoming healthcare investor conferences. The details are as follows:

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcystic lymphatic malformations completed enrollment, exceeding enrollment target by over 25%; top-line results on track for the first quarter of 2026

Palvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

WAYNE, Pa., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced that it will report its second quarter 2025 financial results on Thursday, August 14, 2025. Palvella management will host a conference call for investors at 8:30 a.m.

Palvella Therapeutics to Host Second Quarter 2025 Financial Results and Corporate Update Conference Call on August 14, 2025

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 1:00 p.m. ET.

Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

WAYNE, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc . (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced it has been added to the broad-market Russell 3000® Index and the Russell 2000® Index, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution.

Palvella Therapeutics Added to Russell 3000® and Russell 2000® Indexes

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Enrollment of 51 subjects highlights significant unmet need in this serious, lifelong genetic disease which currently has no FDA-approved therapies

Palvella Therapeutics Completes Enrollment in Phase 3 SELVA Trial of QTORIN™ Rapamycin for Microcystic Lymphatic Malformations, Exceeding Enrollment Target by Over 25%

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

New intellectual property builds on Palvella's multi-layered exclusivity strategy Patent term expected through at least 2038 WAYNE, Pa., June 18, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the United States Patent and Trademark Office (USPTO) issued patent No.

Palvella Therapeutics Granted Sixth U.S. Patent Covering 0.1–20% Anhydrous Compositions of Rapamycin and Other mTOR Inhibitors

See News Rankings

Charts implemented using Lightweight Charts™